Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO),  announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San Francisco between January 13-16.

During the main track presentation, Samsung Biologics' CEO and President John Rim said, "Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in 2025 with the opening of Bio Campus II and launch of antibody-drug conjugate (ADC) services." He added, "We'll continue to invest in new modalities and technologies to better address client needs, maximizing satisfaction and ensuring the delivery of highest-quality products."